相关实验视频

Updated: Jun 28, 2025

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

皮里米丁的耗尽增强了针对性和免疫治疗组合在急性骨髓性白血病

Ola A Elgamal^1,2, Sydney Fobare^1,2, Sandip Vibhute³

¹Division of Hematology and Oncology, Department of Internal Medicine, College of Medicine, University of Cincinnati, Cincinnati, Ohio, USA.

|April 22, 2024

概括

一种新型的二基酸脱酶抑制剂 (DHODHi),HOSU-53,在治疗急性髓性白血病 (AML) 中表现有前途. 将HOSU-53与免疫疗法,特别是抗CD47结合起来,可以提供治疗潜力,并通过血二酸盐水平改善安全监测.

科学领域:

血液学血液学血液学
在瘤学瘤学.
药理学药理学是指药理学的学科.

背景情况:

急性髓性白血病 (AML) 是一种致命的血液性恶性瘤.
目前的AML差异化促进剂缺乏治愈潜力.
基酸脱酶抑制剂 (DHODHi) 在向AML方面表现有前途.

研究的目的:

评估HOSU-53,一种新型的DHODHi,其在AML治疗中的有效性.
评估HOSU-53与标准护理和免疫疗法的协同效应.
探索血二酸盐 (DHO) 水平作为DHODHi安全性和有效性的药理动力学标志物.

主要方法:

在AML模型中对HOSU-53的单疗法和组合研究.
评估DHODHi对CD38和CD47表面表达的影响.
血DHO水平的药理学监测,以预测耐受性.

主要成果:

HOSU-53显示出显著的单一疗法活性,并且在组合疗法中提高了疗效.
DHODHi调节了CD38和CD47的表达,导致抗CD47治疗具有强大的抗白血病效应.
血DHO水平与HOSU-53不耐受性相关,使预测性安全监测成为可能.

结论:

HOSU-53在侵袭性AML中表现出令人信服的治愈潜力,特别是当与抗CD47.7等免疫疗法相结合时.
血DHO的药理动力学监测提供了一种优化DHOHi治疗指数的策略.
数据支持HOSU-53用于AML治疗的临床转化,特别是与基于免疫的策略相结合.

关键词:

癌症免疫疗法癌症免疫疗法药物治疗是药物治疗.在白血病中,白血病.在瘤学瘤学.治疗方法治疗方法

更多相关视频

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.